Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with ...

Detroit Lions legend Barry Sanders has let a terrifying personal experience guide him to advocate for a very important cause ...

Mirae Asset Global Investments trimmed its Amgen holdings by 1.5% in the first quarter, selling 7,398 shares. This reduction ...

In a European study, higher consumption of fruits, vegetables, legumes, and potatoes was associated with a reduced risk of ...

Levelpath, a procurement software startup founded by the duo behind Scout RFP, has raised $55 million in Series B funding led ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Thanks to his trusty Dexcom continuous glucose monitor (CGM), former boy band star Lance Bass is saying “bye bye bye” to ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

According to the latest study from BCC Research, "Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic ...

Europe’s industrial and energy transition is creating long-duration opportunities in infrastructure, utilities and renewables ...

FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare neuromuscular disease.

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...